The route of the march, from South Common along the A15 to the peace camp site opposite RAF Waddington, involved road closures in phases to limit inconvenience to motorists.
Our shape optimization framework is able to minimize the impact of the foot with the ground during the heel-strike phase and to limit foot rotation in case of perturbations.
The purpose of the structure and individual phases is to limit group dynamics and dynamics of social power.
To evaluate the effect of the treatment with imatinib mesylate on SSc-ILD, the study was structured according to Simon's optimal two-stage design [ 16], a strategy devised for phase II studies to limit the number of subjects who will undergo inefficacious therapy, consisting of two subsequent enrolment phases [ 16, 17].
The goal of cross validation is to define a dataset to test the model in the training phase, in order to limit overfitting and give an insight on how the model will generalize to an independent dataset.
The patient's sympathetic response to laryngoscopy was successfully treated with intermittent intravenous (IV) doses of esmolol, and this β1 selective antagonist was also periodically used during the maintenance phase of anesthesia to limit increases in HR from surgical stimulation.
The major challenge of immunosuppressive drugs in the healing phase will be to limit detrimental innate immune influences while simultaneously maintaining and stimulating adequate and appropriate innate immune mechanisms.
The search was applied, from 1990 to 2014 (last search February 5th, 2014) and an additional exclusion criterion was introduced, after the full-text screening phase, in order to limit the analysis to articles submitted after the publication of the first JCIH position statement (October 2000) [ 27] with quality indicators and benchmarks.
During the open-label phase, time to limiting angina was maintained in patients assigned to ivabradine in the first part of the trial, and it increased in patients who had initially received placebo during the first phase.
During the withdrawal phase, time to limiting angina and time to angina onset were significantly longer (P=0.018 and P=0.002, respectively) in patients who were assigned to remain on ivabradine compared with those receiving placebo.
